An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations

被引:0
|
作者
Junyeong Jin
Gunwoo Park
Jong Bae Park
Soohyun Kim
Hyori Kim
Junho Chung
机构
[1] Seoul National University College of Medicine,Department of Biochemistry and Molecular Biology
[2] Seoul National University College of Medicine,Department of Biomedical Science
[3] Seoul National University College of Medicine,Cancer Research Institute
[4] National Cancer Center,Research Institute
[5] Graduate School of Cancer Science and Policy,Department of Cancer Biomedical Science, National Cancer Center
[6] National Cancer Center,Research Institute
[7] Asan Medical Center,Asan Institute for Life Sciences
来源
Experimental & Molecular Medicine | 2018年 / 50卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Antibody-drug conjugates (ADCs) can selectively deliver cytotoxic agents to tumor cells and are frequently more potent than naked antibodies. However, optimization of the conjugation process between antibodies and cytotoxic agents and characterization of ADCs are laborious and time-consuming processes. Here, we describe a novel ADC platform using a tetravalent bispecific antibody that simultaneously binds to the tumor-associated antigen and a hapten conjugated to a cytotoxic agent. We selected cotinine as the hapten because it is not present in biological systems and is inert and nontoxic. We prepared an anti-epidermal growth factor receptor (EGFR) × cotinine bispecific antibody and mixed it with an equimolar amount of cotinine-conjugated duocarmycin to form the ADC. This ADC showed significant in vitro and in vivo antitumor activity against EGFR-positive, cetuximab-refractory lung adenocarcinoma cells with KRAS mutations.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 30 条
  • [21] Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
    Takahashi, N.
    Yamada, Y.
    Furuta, K.
    Honma, Y.
    Iwasa, S.
    Takashima, A.
    Kato, K.
    Hamaguchi, T.
    Shimada, Y.
    BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2716 - 2727
  • [22] Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation
    Yousefi, Maedeh
    Farzi-Khajeh, Hamed
    Akbarzadeh-Khiavi, Mostafa
    Safary, Azam
    Adibkia, Khosro
    PHARMACEUTICAL SCIENCES, 2024, 30 (04) : 444 - 455
  • [23] Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells
    Suwa, T
    Ueda, M
    Jinno, H
    Ozawa, S
    Kitagawa, Y
    Ando, N
    Kitajima, M
    ANTICANCER RESEARCH, 1999, 19 (5B) : 4161 - 4165
  • [24] Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer.
    Lum, Lawrence G.
    Tri Minh Le
    Choi, Minsig
    Thakur, Archana
    Reilley, Matthew
    Kunk, Paul Raymond
    Deol, Abhinav
    Ballen, Karen K.
    Kindwall-Keller, Tamila L.
    Schalk, Dana
    Kubicka, Ewa
    Huang, Manley
    Philip, Philip Agop
    Aoun, Hussein
    Dyson, Gregory
    Liu, Qin
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Phase I/II clinical and immune responses for locally advanced or metastatic pancreatic cancer using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs)
    Lum, Lawrence
    Tri Le
    Choi, Minsig
    Thakur, Archana
    Reilly, Matthew
    Kunk, Paul
    Deol, Abhinav
    Ballen, Karen
    Kindwall-Keller, Tamila
    Schalk, Dana
    Kubicka, Ewa
    Huang, Manley
    Philip, Philip
    Aoun, Hussein
    Dyson, Gregory
    Liu, Qin
    Shields, Anthony
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] Mutations in NRAS codon 61, KRAS codon 146, and BRAF V600E as prognostic factors in patients who received anti-EGFR antibody for metastatic colorectal cancer.
    Takahashi, Naoki
    Yamada, Yasuhide
    Taniguchi, Hirokazu
    Akiyoshi, Kohei
    Honma, Yoshitaka
    Iwasa, Satoru
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
    Kollmannsberger, C.
    Schittenhelm, M.
    Honecker, F.
    Tillner, J.
    Weber, D.
    Oechsle, K.
    Kanz, L.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 1007 - 1013
  • [28] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
    Brandao, Mariana da Rocha Almeida
    Zugazagoitia, Jon
    Dingemans, Anne-Marie C.
    Duruisseaux, Michael
    Parent, Pauline
    Juan-Vidal, Oscar
    Spira, Alexander I.
    Vicier, Cecile
    Zalcman, Gerard
    Barasa, Ben
    Yan, Chris
    Doze, Petra
    Joe, Andrew K.
    Laus, Gianluca
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells
    Normanno, N
    Tortora, G
    De Luca, A
    Pomatico, G
    Casamassimi, A
    Agrawal, S
    Mendelsohn, J
    Bianco, AR
    Ciardiello, F
    ONCOLOGY REPORTS, 1999, 6 (05) : 1105 - 1109
  • [30] Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer
    Oliveras-Ferraros, Cristina
    Vazquez-Martin, Alejandro
    Lopez-Bonet, Eugeni
    Martin-Castillo, Begona
    Del Barco, Sonia
    Brunt, Joan
    Menendez, Javier A.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (06) : 1165 - 1176